Bruno M. Costa

Lymphoproliferative Disorder Involving Body Fluid

A. Becker, L. Neder, C. Clara, 2022 .

A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial

M. Dimopoulos, M. Mohty, A. Belch, 2019, Leukemia.

Predictors of Lenalidomide Refractory Relapse Timing With Newly Diagnosed Multiple Myeloma: A FIRST Trial Subanalysis.

M. Dimopoulos, X. Leleu, M. Delforge, 2023, Clinical lymphoma, myeloma & leukemia.

A predictive model for risk of early grade ≥ 3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial

M. Dimopoulos, J. H. Lee, M. Mohty, 2018, Leukemia.

Carfilzomib, Pomalidomide and Dexamethasone (KPd) in Patients with Multiple Myeloma Refractory to Bortezomib and Lenalidomide. the EMN011 Trial

K. Nasserinejad, P. Sonneveld, M. Boccadoro, 2018, Blood.

A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial

M. Dimopoulos, M. Mohty, A. Belch, 2019, Leukemia.